Berkshire Hathaway Inc Acquires Shares of 28,880,209 DaVita Inc. $DVA

Posted by Brian Himes on Aug 27th, 2026

Berkshire Hathaway Inc acquired a new stake in shares of DaVita Inc. (NYSE:DVA – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 28,880,209 shares of the company’s stock, valued at approximately $6,425,269,000. DaVita makes up about 2.1% of Berkshire Hathaway Inc’s investment portfolio, making the stock its 11th biggest position. Berkshire Hathaway Inc owned 0.45% of DaVita at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DVA. BlackRock Inc. purchased a new position in DaVita during the second quarter valued at $547,520,000. Invesco Ltd. increased its holdings in DaVita by 2.0% in the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after acquiring an additional 32,358 shares during the last quarter. Morgan Stanley lifted its stake in DaVita by 5.1% in the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after purchasing an additional 71,156 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of DaVita by 5.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock valued at $176,037,000 after purchasing an additional 56,336 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.90% of the stock is owned by insiders.

DaVita Price Performance

Shares of DVA stock opened at $180.34 on Thursday. The company has a market cap of $11.51 billion, a PE ratio of 14.76, a price-to-earnings-growth ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The stock’s 50 day simple moving average is $213.07 and its two-hundred day simple moving average is $182.80.

DaVita (NYSE:DVA – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DVA. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. UBS Group raised their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Oppenheimer set a $220.00 price objective on DaVita in a research note on Friday, August 7th. Finally, Truist Financial lowered their target price on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $221.75.

View Our Latest Research Report on DaVita

DaVita Profile

(Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.